SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is actively trending following Saudi FDA approval for its Anktiva treatment in lung cancer, sparking widespread community discussion about its potential as a game-changing, chemotherapy-free cancer therapy and its global expansion. This news, amplified by public statements from Dr. Patrick Soon-Shiong, is driving intense speculation regarding a short squeeze amidst high market interest.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to renewed geopolitical uncertainty as Trump's tariff threats over Greenland escalate US-EU tensions, causing futures to dip. The community is sharply divided, with bears anticipating a significant market correction, while bulls expect a "buy the dip" scenario, recalling previous tariff-related downturns that quickly reversed.

Oasis is a layer-one blockchain built to support confidential applications at scale. It’s home to Sapphire, the world’s first private EVM network, Oasis Privacy Layer, a cross-chain privacy solution for any EVM dApp, and Runtime Offchain Logic, a framework that brings trustworthy off-chain computing, onchain. Powered by its ROSE token, Oasis leverages a unique layered architecture and native rollup support, making it ideal for use cases in AI, DeFi, DAOs, gaming, and more.

Oasis Network

Oasis Network (ROSE) is trending due to its pivotal role in privacy-preserving AI and Web3 infrastructure, notably through its Sapphire runtime which secures AI agents and decentralized applications. The community is actively discussing its strong utility and recent collaborations, with many seeing ROSE as an undervalued asset poised for significant growth in the burgeoning privacy and AI sectors.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is experiencing heightened volatility due to a fresh short report alleging questionable business practices and broader weakness in the ad tech sector. The community is actively debating if recent price movements are fueled by market manipulation and short-selling pressure ahead of anticipated strong earnings. Many bullish investors are emphasizing the company's AI-driven growth, expanding market reach, and recent analyst upgrades, viewing current price levels as a potential buying opportunity.

Alchemy Pay

Alchemy Pay is trending due to significant developments, including its upcoming Level 1 Alchemy Chain and numerous new partnerships and Money Transmitter Licenses expanding its global fiat-crypto on-ramp services. The community is vigorously debating its potential as a payment infrastructure solution, with strong bullish sentiment driven by its enhanced utility and tokenomics.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending due to buzz around a massive US government contract for its Foundry Services and increasing speculation that Apple could become a key manufacturing client. This news, coupled with recent analyst upgrades, has bulls anticipating a significant rally post-earnings, while skeptics point to potential price manipulation and a stretched valuation. The stock's performance is seen as a barometer for the future of domestic chip manufacturing and its role in the booming AI sector.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to significant insider confidence, highlighted by a director's recent share purchase, and the official groundbreaking of its $100 billion U.S. megafab. The community is actively discussing an unprecedented and sustained shortage in memory chips, especially for AI, driving strong bullish sentiment around the company's strategic expansions and HBM products. Investors are anticipating continued growth as Micron addresses escalating demand.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid anticipation of a Supreme Court ruling on tariffs, which could influence inflation and trade stability, alongside ongoing discussions regarding political pressure on the Federal Reserve's independence. This has created a divided community, with some viewing long-term bonds as a potential recession hedge, while others remain bearish due to persistent yield concerns and broader economic uncertainty.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending with strong community conviction, driven by its unique model as a "permissionless brand" actively building real-world products and businesses. The bullish community celebrates its relentless "IRL" efforts, including launching Kendu Spice on Amazon and developing Kendu Energy drinks and entertainment initiatives. Available across Ethereum, Solana, and Base, KENDU is seen as a long-term play with dedicated holders who believe it's establishing a new paradigm for decentralized branding.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF is actively discussed amid ongoing US-Europe trade tensions, particularly surrounding escalating tariff threats and Europe's planned fiscal stimulus for defense and infrastructure. Community sentiment remains largely bullish, focusing on Elliott Wave technical setups that suggest continued upside potential, despite recent volatility and broader economic concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Decreases By 29.2%

IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 2,015,986 shares, a...

IO Biotech (NASDAQ:IOBT) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded shares of IO Biotech from a "hold" rating to a "sell" rating in a report on Monday...

IO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Recommendation of "Hold" from Analysts

IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) has been assigned a consensus rating of "Hold" from the six research firms that are presently covering the company, Marketbeat reports. One analyst...

Wall Street Zen downgraded shares of IO Biotech from a "hold" rating to a "sell" rating in a report on Saturday...

IO Biotech (NASDAQ:IOBT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised IO Biotech from a "sell" rating to a "hold" rating in a research report on Sunday...

IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why

IO Biotech, Inc. (IOBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology PR Newswire NEW...

IO Biotech (IOBT) stock slumped 77% by Monday afternoon after the company announced that the U.S. Food and Drug Administration (FDA) recommended that the firm conduct another trial before submitting Cylembio for approval.IO Biotech held a meeting with the agency, which recommended that the firm not submit an application based on data from the IOB-013 clinical trial, in which Cylembio plus Merck’s Pembrolizumab improved progression-free survival (PFS), but narrowly missed statistical significance.“We look forward to continuing the dialogue with FDA to align on the design for a potential new registrational study. Additionally, we plan to discuss the data from our IOB-013 study with European regulators and determine a path to submission in the EU,” CEO Mai-Britt Zocca <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.iobiotech.com/news-events/news/news-details/2025/IO-Biotech-Provides-Update-Following-Pre-BLA-Meeting-with-FDA/default.aspx">said</a>.The company also stated that it is implementing a plan to conserve capital while seeking approval for the drug and conducting ongoing studies. IO Biotech currently has capital to sustain its operation into the first quarter of 2026. However, it is now planning restructuring, including a halving of its workforce.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IOBT">IOBT stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_2_10_50_PM_png_0d2cc62fff.webp" alt="IOBT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>IOBT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>Following the company’s announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target, as per TheFly. Given its cash position, the company would either need to raise additional capital, partner, or license out Cylembio to advance the new trial, the analyst noted.IO Biotech had <a href="https://stocktwits.com/news-articles/markets/equity/io-biotech-trial-of-cancer-therapy-plus-keytruda-misses-study-goal/chrHGKVRdeB">announced</a> in August that the late-stage trial of its investigational and therapeutic cancer vaccine, Cylembio, in combination with Pembrolizumab, failed to achieve statistical significance in terms of progression-free survival improvement compared to Keytruda alone.The trial evaluated Cylembio in combination with Keytruda versus Keytruda alone in 407 patients with previously untreated, unresectable, or metastatic (advanced) melanoma. Patients in the study treated with Cylembio in combination with Keytruda achieved a median progression-free survival of 19.4 months, compared to 11.0 months in patients treated with Keytruda alone. Progression-free survival (PFS) refers to the duration of time during and after cancer treatment during which a patient lives without the disease worsening.IOBT stock is down 61% this year and approximately 66% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/enanta-pharmaceuticals-stock-rises-despite-rsv-treatment-mid-stage-trial-failing-main-goal/chDuJaER3JS">Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

IO Biotech Stock Plunges After FDA Recommends Another Trial For Investigational Cancer Vaccine

Following the announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target. 

Equity

Following the announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target. 


IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know

IO Biotech, Inc. (IOBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

IO Biotech (IOBT) announced on Monday that its investigational and therapeutic cancer vaccine, Cylembio, in combination with Merck’s (MRK) Keytruda, failed to achieve statistical significance in progression-free survival improvement in a late-stage trial compared to Keytruda alone.IOBT stock traded over 19% lower on Monday morning, at the time of writing. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://iobiotech.com/press-releases/?workflow=6562e614-30a0-4300-9a37-ab75253933a2">said</a> Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed. Improvement in progression-free survival was achieved across virtually all subgroups, including those with poor prognostic factors, the company said.The trial evaluated Cylembio in combination with Keytruda versus Keytruda alone in 407 patients with previously untreated, unresectable, or metastatic (advanced) melanoma. Patients in the study treated with Cylembio in combination with Keytruda achieved 19.4 months of median progression-free survival compared to 11.0 months in patients treated with Keytruda alone. Progression-free survival (PFS) refers to the length of time during and after cancer treatment that a patient lives without the disease worsening.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IOBT">IOBT</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_9_43_00_AM_png_243b1797b9.webp" alt="IOBT's Sentiment Meter and Message Volume as of 9:43 a.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>IOBT's Sentiment Meter and Message Volume as of 9:43 a.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the data.<stembedurl>https://stocktwits.com/Notnotshort/message/624573071</stembedurl>Another opined that the stock price should multiply by 10 times in the aftermath of the data release.<stembedurl>https://stocktwits.com/Abo_Hamza/message/624572510</stembedurl>A trend toward an improvement in overall survival was also observed in the study, though data is not yet mature, the company said. Overall survival (OS) is a key metric in clinical trials, particularly for cancer, representing the length of time from a specific event (like diagnosis or treatment start) that patients remain alive.“The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data,” said Mai-Britt Zocca, CEO of IO Biotech.IO Biotech plans to meet with the U.S. Food and Drug Administration (FDA) this fall to discuss the data and determine next steps for submission of a Biologics License Application (BLA) for the treatment of advanced melanoma.IOBT stock is up by 59% this year and by about 12% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/kroger-reaches-settlement-with-c-and-s-wholesale-grocers/chruzkSRdec">Big News On Kroger! Company Reaches Settlement With C&amp;S Wholesale Grocers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x

The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed.

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Current Price	$0.5021
Prev Close	$0.516
Open	$0.516
Dividend Yield	0.00%
50-Day Moving Average	$0.706
Beta	0.84
Avg. Volume	788,042.68
PE Ratio	-0.37

52-Week High	$2.79
52-Week Low	$0.3234
Market Capitalization	$36.13M
EPS (Annual)	-$1.45
Price to Book	38.42
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IOBT
IO Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IOBT News

IOBTIO Biotech Inc